Pre-exposure (PrEP)
Pre-exposure Prophylaxis (PrEP)
IAS 2015: ADAPT Study Shows PrEP Feasibility [VIDEO]
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Thursday, 20 August 2015 00:00
- Written by Gregory Fowler
Results from the HPTN 067 or ADAPT trial -- a study of Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis for gay men in New York City and Bangkok, and heterosexual women in Cape Town -- add to the growing body of evidence about how best to use PrEP and how its protective effect may vary across population groups and with different dosing schedules, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.
IAS 2015: First Brazilian Data Reinforce Evidence that PrEP is Mostly Used by Those at Greatest Risk
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 18 August 2015 00:00
- Written by Gus Cairns
The first data from a Brazilian open-label demonstration project of HIV pre-exposure prophylaxis (PrEP) show, in common with several other studies presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver, that the higher a person’s risk of HIV infection, the more likely they are to seek and use PrEP.
IAS 2015: Pros and Cons of PrEP -- Volunteers Recount their Experiences in ADAPT Study
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 05 August 2015 00:00
- Written by Gus Cairns
The reasons people come forward for pre-exposure prophylaxis (PrEP) or take it once prescribed are likely to be very mixed, and dependent as much on local political and cultural beliefs as they are on more personal factors like relationship status, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) last month in Vancouver.
IAS 2015: High Adherence and No HIV Infections Seen in Heterosexual PrEP Study in Botswana
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 11 August 2015 00:00
- Written by Gus Cairns
A study of open-label Truvada HIV pre-exposure prophylaxis (PrEP) among heterosexual people in Botswana found very high adherence rates. Around 90% of participants had useful levels of the drug in their blood, there was a high concordance between self-reported adherence and drug levels, and there were no HIV infections, according to a presentation at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.
IAS 2015: People with Hepatitis B Can Safely Use Truvada PrEP for HIV Prevention
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 05 August 2015 00:00
- Written by Liz Highleyman
People with hepatitis B virus (HBV) infection did not experience liver inflammation "flares" or other adverse events when they used or stopped using Truvada for HIV pre-exposure prophylaxis (PrEP), according to an analysis from the iPrEx study presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last month in Vancouver. This is a potential concern because the drugs in Truvada -- tenofovir and emtricitabine -- are active against HBV as well as HIV.
More Articles...
- IAS 2015: Gay Youth PrEP Study Finds Good Retention and Reasonable Adherence
- IAS 2015: U.S. PrEP Demo Project Finds People at Highest HIV Risk Take PrEP Most Consistently
- IAS 2015: Intermittent PrEP May Be Robust Strategy for Anal Sex -- Vaginal Protection Less Certain
- IAS 2015: Non-Daily PrEP Provides Extra Options, But Adherence Often Better with Daily Dosing
Web Design and Development by